Pharmacogenetics-Based New Therapeutic Concepts
Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Pharmac...
Gespeichert in:
| Veröffentlicht in: | Drug metabolism reviews 2004, Vol.36 (3-4), p.617-638 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 638 |
|---|---|
| container_issue | 3-4 |
| container_start_page | 617 |
| container_title | Drug metabolism reviews |
| container_volume | 36 |
| creator | Roots, Ivar Gerloff, Thomas Meisel, Christian Kirchheiner, Julia Goldammer, Mark Kaiser, Rolf Laschinski, Gabriele Brockmöller, Jürgen Cascorbi, Ingolf Kleeberg, Ullrich Hildebrandt, Alfred G. |
| description | Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Pharmacogenetics adds a considerable amount of stringency to the doctor's therapeutic approach. Today, it is the relationship between dosage requirements and genetic variations in drug metabolizing enzymes like cytochrome P450 (CYP) 2D6 and CYP2C19, or in drug transporters like p-glycoprotein, that is substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better due to higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. The drug's interaction with its target (e.g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market. |
| doi_str_mv | 10.1081/DMR-200033458 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1081_DMR_200033458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67081443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-c3bc8ab76e27de1005684ec2f7f1d05775bb70d9b790041885a92aa2b50e28ad3</originalsourceid><addsrcrecordid>eNp1kEFP3DAQRi1U1F1oj1zRXtpbytiOY-cIS0uRFlohOFsTZ8JmlY0XOxHi39fVLiAOexpp9L5PM4-xEw4_OBh-dnlzlwkAkDJX5oBNOZQ6K42Rn9gUZAGZUFJM2FGMKwAuSqU_swlXSuVCllN29neJYY3OP1JPQ-tidoGR6tktPc_ulxRwQ2Naz-a-d7QZ4hd22GAX6etuHrOHXz_v57-zxZ-r6_n5InM5L4bMycoZrHRBQtfEAVRhcnKi0Q2vQWmtqkpDXVa6BMi5MQpLgSgqBSQM1vKYfd_2boJ_GikOdt1GR12HPfkx2kKn5_NcJjDbgi74GAM1dhPaNYYXy8H-N2STIftmKPGnu-KxWlP9Tu-UJODbDsDosGsC9q6N71whuFElJM5subZvfFL47ENX2wFfOh9eQ3LfDfpDdEnYDUuHgezKj6FPYvdc_w8gOJD9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67081443</pqid></control><display><type>article</type><title>Pharmacogenetics-Based New Therapeutic Concepts</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Roots, Ivar ; Gerloff, Thomas ; Meisel, Christian ; Kirchheiner, Julia ; Goldammer, Mark ; Kaiser, Rolf ; Laschinski, Gabriele ; Brockmöller, Jürgen ; Cascorbi, Ingolf ; Kleeberg, Ullrich ; Hildebrandt, Alfred G.</creator><creatorcontrib>Roots, Ivar ; Gerloff, Thomas ; Meisel, Christian ; Kirchheiner, Julia ; Goldammer, Mark ; Kaiser, Rolf ; Laschinski, Gabriele ; Brockmöller, Jürgen ; Cascorbi, Ingolf ; Kleeberg, Ullrich ; Hildebrandt, Alfred G.</creatorcontrib><description>Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Pharmacogenetics adds a considerable amount of stringency to the doctor's therapeutic approach. Today, it is the relationship between dosage requirements and genetic variations in drug metabolizing enzymes like cytochrome P450 (CYP) 2D6 and CYP2C19, or in drug transporters like p-glycoprotein, that is substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better due to higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. The drug's interaction with its target (e.g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market.</description><identifier>ISSN: 0360-2532</identifier><identifier>EISSN: 1097-9883</identifier><identifier>DOI: 10.1081/DMR-200033458</identifier><identifier>PMID: 15554239</identifier><identifier>CODEN: DMTRAR</identifier><language>eng</language><publisher>New York, NY: Informa UK Ltd</publisher><subject>Animals ; Biological and medical sciences ; CYP2C19 ; CYP2D6 ; Cytochrome P-450 Enzyme System - genetics ; Cytochrome P-450 Enzyme System - metabolism ; Drug transporters ; General pharmacology ; Genetic Variation - drug effects ; Genetic Variation - genetics ; Humans ; Individualized medicine ; Medical sciences ; Pharmaceutical Preparations - administration & dosage ; Pharmaceutical Preparations - metabolism ; Pharmacogenetics ; Pharmacogenetics - methods ; Pharmacogenetics - statistics & numerical data ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Polymorphism, Single Nucleotide - drug effects ; Polymorphism, Single Nucleotide - genetics ; Proton pump inhibitors ; Xenobiotics - metabolism</subject><ispartof>Drug metabolism reviews, 2004, Vol.36 (3-4), p.617-638</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-c3bc8ab76e27de1005684ec2f7f1d05775bb70d9b790041885a92aa2b50e28ad3</citedby><cites>FETCH-LOGICAL-c416t-c3bc8ab76e27de1005684ec2f7f1d05775bb70d9b790041885a92aa2b50e28ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1081/DMR-200033458$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1081/DMR-200033458$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,4023,27922,27923,27924,59646,59752,60435,60541,61220,61255,61401,61436</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16218590$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15554239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roots, Ivar</creatorcontrib><creatorcontrib>Gerloff, Thomas</creatorcontrib><creatorcontrib>Meisel, Christian</creatorcontrib><creatorcontrib>Kirchheiner, Julia</creatorcontrib><creatorcontrib>Goldammer, Mark</creatorcontrib><creatorcontrib>Kaiser, Rolf</creatorcontrib><creatorcontrib>Laschinski, Gabriele</creatorcontrib><creatorcontrib>Brockmöller, Jürgen</creatorcontrib><creatorcontrib>Cascorbi, Ingolf</creatorcontrib><creatorcontrib>Kleeberg, Ullrich</creatorcontrib><creatorcontrib>Hildebrandt, Alfred G.</creatorcontrib><title>Pharmacogenetics-Based New Therapeutic Concepts</title><title>Drug metabolism reviews</title><addtitle>Drug Metab Rev</addtitle><description>Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Pharmacogenetics adds a considerable amount of stringency to the doctor's therapeutic approach. Today, it is the relationship between dosage requirements and genetic variations in drug metabolizing enzymes like cytochrome P450 (CYP) 2D6 and CYP2C19, or in drug transporters like p-glycoprotein, that is substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better due to higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. The drug's interaction with its target (e.g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>CYP2C19</subject><subject>CYP2D6</subject><subject>Cytochrome P-450 Enzyme System - genetics</subject><subject>Cytochrome P-450 Enzyme System - metabolism</subject><subject>Drug transporters</subject><subject>General pharmacology</subject><subject>Genetic Variation - drug effects</subject><subject>Genetic Variation - genetics</subject><subject>Humans</subject><subject>Individualized medicine</subject><subject>Medical sciences</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmaceutical Preparations - metabolism</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenetics - methods</subject><subject>Pharmacogenetics - statistics & numerical data</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymorphism, Single Nucleotide - drug effects</subject><subject>Polymorphism, Single Nucleotide - genetics</subject><subject>Proton pump inhibitors</subject><subject>Xenobiotics - metabolism</subject><issn>0360-2532</issn><issn>1097-9883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFP3DAQRi1U1F1oj1zRXtpbytiOY-cIS0uRFlohOFsTZ8JmlY0XOxHi39fVLiAOexpp9L5PM4-xEw4_OBh-dnlzlwkAkDJX5oBNOZQ6K42Rn9gUZAGZUFJM2FGMKwAuSqU_swlXSuVCllN29neJYY3OP1JPQ-tidoGR6tktPc_ulxRwQ2Naz-a-d7QZ4hd22GAX6etuHrOHXz_v57-zxZ-r6_n5InM5L4bMycoZrHRBQtfEAVRhcnKi0Q2vQWmtqkpDXVa6BMi5MQpLgSgqBSQM1vKYfd_2boJ_GikOdt1GR12HPfkx2kKn5_NcJjDbgi74GAM1dhPaNYYXy8H-N2STIftmKPGnu-KxWlP9Tu-UJODbDsDosGsC9q6N71whuFElJM5subZvfFL47ENX2wFfOh9eQ3LfDfpDdEnYDUuHgezKj6FPYvdc_w8gOJD9</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Roots, Ivar</creator><creator>Gerloff, Thomas</creator><creator>Meisel, Christian</creator><creator>Kirchheiner, Julia</creator><creator>Goldammer, Mark</creator><creator>Kaiser, Rolf</creator><creator>Laschinski, Gabriele</creator><creator>Brockmöller, Jürgen</creator><creator>Cascorbi, Ingolf</creator><creator>Kleeberg, Ullrich</creator><creator>Hildebrandt, Alfred G.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Pharmacogenetics-Based New Therapeutic Concepts</title><author>Roots, Ivar ; Gerloff, Thomas ; Meisel, Christian ; Kirchheiner, Julia ; Goldammer, Mark ; Kaiser, Rolf ; Laschinski, Gabriele ; Brockmöller, Jürgen ; Cascorbi, Ingolf ; Kleeberg, Ullrich ; Hildebrandt, Alfred G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-c3bc8ab76e27de1005684ec2f7f1d05775bb70d9b790041885a92aa2b50e28ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>CYP2C19</topic><topic>CYP2D6</topic><topic>Cytochrome P-450 Enzyme System - genetics</topic><topic>Cytochrome P-450 Enzyme System - metabolism</topic><topic>Drug transporters</topic><topic>General pharmacology</topic><topic>Genetic Variation - drug effects</topic><topic>Genetic Variation - genetics</topic><topic>Humans</topic><topic>Individualized medicine</topic><topic>Medical sciences</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmaceutical Preparations - metabolism</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenetics - methods</topic><topic>Pharmacogenetics - statistics & numerical data</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymorphism, Single Nucleotide - drug effects</topic><topic>Polymorphism, Single Nucleotide - genetics</topic><topic>Proton pump inhibitors</topic><topic>Xenobiotics - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roots, Ivar</creatorcontrib><creatorcontrib>Gerloff, Thomas</creatorcontrib><creatorcontrib>Meisel, Christian</creatorcontrib><creatorcontrib>Kirchheiner, Julia</creatorcontrib><creatorcontrib>Goldammer, Mark</creatorcontrib><creatorcontrib>Kaiser, Rolf</creatorcontrib><creatorcontrib>Laschinski, Gabriele</creatorcontrib><creatorcontrib>Brockmöller, Jürgen</creatorcontrib><creatorcontrib>Cascorbi, Ingolf</creatorcontrib><creatorcontrib>Kleeberg, Ullrich</creatorcontrib><creatorcontrib>Hildebrandt, Alfred G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug metabolism reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roots, Ivar</au><au>Gerloff, Thomas</au><au>Meisel, Christian</au><au>Kirchheiner, Julia</au><au>Goldammer, Mark</au><au>Kaiser, Rolf</au><au>Laschinski, Gabriele</au><au>Brockmöller, Jürgen</au><au>Cascorbi, Ingolf</au><au>Kleeberg, Ullrich</au><au>Hildebrandt, Alfred G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenetics-Based New Therapeutic Concepts</atitle><jtitle>Drug metabolism reviews</jtitle><addtitle>Drug Metab Rev</addtitle><date>2004</date><risdate>2004</risdate><volume>36</volume><issue>3-4</issue><spage>617</spage><epage>638</epage><pages>617-638</pages><issn>0360-2532</issn><eissn>1097-9883</eissn><coden>DMTRAR</coden><abstract>Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Pharmacogenetics adds a considerable amount of stringency to the doctor's therapeutic approach. Today, it is the relationship between dosage requirements and genetic variations in drug metabolizing enzymes like cytochrome P450 (CYP) 2D6 and CYP2C19, or in drug transporters like p-glycoprotein, that is substantiated best. A standard dose will bring about more adverse effects than usual if enzymatic activity is lacking or feeble. Sometimes, however, therapeutic response might be better due to higher concentrations: proton pump inhibitors for eradication of Helicobacter pylori are more efficacious in carriers of a deficient CYP2C19 variant. The drug's interaction with its target (e.g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market.</abstract><cop>New York, NY</cop><pub>Informa UK Ltd</pub><pmid>15554239</pmid><doi>10.1081/DMR-200033458</doi><tpages>22</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-2532 |
| ispartof | Drug metabolism reviews, 2004, Vol.36 (3-4), p.617-638 |
| issn | 0360-2532 1097-9883 |
| language | eng |
| recordid | cdi_crossref_primary_10_1081_DMR_200033458 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Animals Biological and medical sciences CYP2C19 CYP2D6 Cytochrome P-450 Enzyme System - genetics Cytochrome P-450 Enzyme System - metabolism Drug transporters General pharmacology Genetic Variation - drug effects Genetic Variation - genetics Humans Individualized medicine Medical sciences Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - metabolism Pharmacogenetics Pharmacogenetics - methods Pharmacogenetics - statistics & numerical data Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Polymorphism, Single Nucleotide - drug effects Polymorphism, Single Nucleotide - genetics Proton pump inhibitors Xenobiotics - metabolism |
| title | Pharmacogenetics-Based New Therapeutic Concepts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A45%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenetics-Based%20New%20Therapeutic%20Concepts&rft.jtitle=Drug%20metabolism%20reviews&rft.au=Roots,%20Ivar&rft.date=2004&rft.volume=36&rft.issue=3-4&rft.spage=617&rft.epage=638&rft.pages=617-638&rft.issn=0360-2532&rft.eissn=1097-9883&rft.coden=DMTRAR&rft_id=info:doi/10.1081/DMR-200033458&rft_dat=%3Cproquest_cross%3E67081443%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67081443&rft_id=info:pmid/15554239&rfr_iscdi=true |